Eupraxia Pharmaceuticals (NASDAQ:EPRX) Given New $11.00 Price Target at HC Wainwright

Eupraxia Pharmaceuticals (NASDAQ:EPRX) had its target price reduced by HC Wainwright from $12.00 to $11.00 in a research note released on Tuesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other research analysts have also recently issued reports on EPRX. Wall Street Zen downgraded shares of Eupraxia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, February 21st. Lifesci Capital upgraded shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, December 11th. Cantor Fitzgerald boosted their target price on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an “overweight” rating in a research note on Thursday, January 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $15.00.

Eupraxia Pharmaceuticals Trading Up 2.6%

Shares of Eupraxia Pharmaceuticals stock opened at $7.58 on Tuesday. The stock has a market capitalization of $272.58 million, a price-to-earnings ratio of -7.36 and a beta of 1.27. The firm’s 50-day moving average price is $8.29 and its two-hundred day moving average price is $6.87. Eupraxia Pharmaceuticals has a 1-year low of $2.68 and a 1-year high of $9.32.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its earnings results on Thursday, March 19th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.21). As a group, equities research analysts predict that Eupraxia Pharmaceuticals will post -0.67 EPS for the current year.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

Large investors have recently modified their holdings of the business. Guardian Wealth Advisors LLC NC acquired a new position in shares of Eupraxia Pharmaceuticals in the 4th quarter valued at approximately $76,000. Aptus Capital Advisors LLC bought a new position in Eupraxia Pharmaceuticals in the fourth quarter valued at approximately $76,000. Bank of America Corp DE lifted its stake in Eupraxia Pharmaceuticals by 402.4% in the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after buying an additional 10,059 shares in the last quarter. Quadrature Capital Ltd acquired a new position in shares of Eupraxia Pharmaceuticals in the second quarter valued at approximately $61,000. Finally, TCI Wealth Advisors Inc. acquired a new position in shares of Eupraxia Pharmaceuticals in the third quarter valued at approximately $65,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.